KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Cost of Revenue (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Cost of Revenue for 4 consecutive years, with -$39.9 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Cost of Revenue rose 73.97% year-over-year to -$39.9 million, compared with a TTM value of -$13.3 million through Dec 2023, down 164.39%, and an annual FY2025 reading of $28.9 million, changed N/A over the prior year.
  • Cost of Revenue was -$39.9 million for Q4 2023 at Ginkgo Bioworks Holdings, down from $6.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $163.5 million in Q3 2022 and bottomed at -$153.4 million in Q4 2022.
  • Average Cost of Revenue over 4 years is $2.2 million, with a median of $6.0 million recorded in 2023.
  • The sharpest move saw Cost of Revenue skyrocketed 966.82% in 2021, then plummeted 536.87% in 2022.
  • Year by year, Cost of Revenue stood at $1.8 million in 2020, then crashed by 1677.73% to -$27.9 million in 2021, then tumbled by 449.45% to -$153.4 million in 2022, then soared by 73.97% to -$39.9 million in 2023.
  • Business Quant data shows Cost of Revenue for DNA at -$39.9 million in Q4 2023, $6.0 million in Q3 2023, and $16.1 million in Q2 2023.